Biodesix (BDSX) – Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Biodesix (NASDAQ: BDSX) in the last few weeks:

• 6/24/2026 – Biodesix is now covered by Roth Mkm. They set a “buy” rating and a $32.00 price target on the stock.
• 6/24/2026 – Biodesix was upgraded by Roth Mkm to “strong-buy”.
• 6/18/2026 – Biodesix had its price target raised by Canaccord Genuity Group Inc. from $22.00 to $27.00. They now have a “buy” rating on the stock.
• 6/15/2026 – Biodesix is now covered by HC Wainwright. They set a “buy” rating and a $26.00 price target on the stock.
• 6/15/2026 – Biodesix is now covered by HC Wainwright. They set a “buy” rating and a $26.00 price target on the stock.
• 6/12/2026 – Biodesix was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 5/18/2026 – Biodesix was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/5/2026 – Biodesix had its price target raised by Canaccord Genuity Group Inc. from $20.00 to $22.00. They now have a “buy” rating on the stock.
• 5/4/2026 – Biodesix had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.